Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody
The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion.
The drug, UCB0107, is designed to impede or decrease the buildup of tau proteins in the brain, which leads to nerve cell damage and death. UCB is already developing it for progressive supranuclear palsy (PSP), an uncommon neurodegenerative disorder, which affects movement, gait, balance, speech, vision, mood and behaviour.
Under the agreement, UCB will fund...
